Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q1 2018 · 10-Q
Revenue$379.00K$379.00K+24.3% vs Q1 2017 Net Income-$19.40M-$19.40MN/M vs Q1 2017 EPS Diluted$0.79$0.79N/M vs Q1 2017 Operating Income-$19,751,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
Free Cash Flowderived-$20,043,000— Margins · derivedOperating margin-5211.3%−891.0 pt vs Q1 2017
Net margin-5118.2%−865.4 pt vs Q1 2017
ended Mar 31, 2018 · filed May 9, 2018 · 39 d after period end